Healthcare Equipment and Supplies
Company Overview of AxoGen, Inc.
AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offe...
13631 Progress Boulevard
Alachua, FL 32615
Key Executives for AxoGen, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $473.3K
Chief Financial Officer
Total Annual Compensation: $220.9K
Senior Vice President of Business Development, General Counsel and Director
Total Annual Compensation: $326.8K
Senior Vice President of Sales
Total Annual Compensation: $384.3K
Chief Marketing Officer
Total Annual Compensation: $311.7K
Compensation as of Fiscal Year 2014.
AxoGen, Inc. Key Developments
AxoGen, Inc. to Report Q1, 2015 Results on May 05, 2015
May 5 15
AxoGen, Inc. announced that they will report Q1, 2015 results After-Market on May 05, 2015
AxoGen, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015
May 5 15
AxoGen, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $4.951 million for the first quarter ended March 31, 2015, a 58% increase compared to $3.138 million in the year-ago first quarter. Loss from operations was $2.543 million against $2.991 million a year ago. Net loss was $3.575 million or $0.16 per basic and diluted share against $4.239 million or $0.24 per basic and diluted share a year ago. Net cash used for operating activities was $2.513 million against $3.150 million a year ago. Purchase of property and equipment was $0.006 million against $0.195 million a year ago. Acquisition of intangible assets was $0.032 million against $0.008 million a year ago.
For the year 2015, the company announced that given the market's increasing awareness of the company’s product portfolio and the company's plans to expand its sales footprint and sales pipeline, the company is reaffirming its 2015 full year revenue guidance of at least $24 million with annual gross margin in the mid to high 70% range.
AxoGen, Inc. - Shareholder/Analyst Call
Apr 27 15
Annual Shareholders Meeting
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries